CANY
PSTX

Caxton Associates (New York)’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Caxton Associates (New York)’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-24,608
Closed -$75.8K – 683
2023
Q1 		$75.8K Buy
+24,608
New +$147K 0.01% 471

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Caxton Associates (New York)'s PSTX Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q2 2023, closing a stake of 24,608 shares — an estimated $75.8K sold.

Caxton Associates (New York) first reported a position in PSTX in Q1 2023 and held it in 1 quarter. The position peaked at $75.8K in Q1 2023. 94 funds tracked by Wall St. Rank hold PSTX as of Q2 2023.

  • Caxton Associates (New York) reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 24,608 Poseida Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $75.8K.
  • Caxton Associates (New York) first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Caxton Associates (New York)'s Poseida Therapeutics, Inc. Common Stock position peaked at $75.8K in Q1 2023.
  • 94 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.